The financing was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, Romania’s Cleverage VC, and Webit Investment Network.
“We welcome this strong international group of investors to our latest round of financing,” said Todor Jeliaskov, Chairman and CEO of inHEART. “This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support. It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.”
In addition, inHEART received funds from a successful crowd equity campaign on Tudigo and from the Astorg Foundation – Astorg Philanthropy Investments – represented and managed by the King Baudouin Foundation.
“We are enthusiastic to continue our support and co-lead this financing round for inHEART,” said Samantha Jérusalmy, board member at inHEART and Partner at Elaia.
Financing from this round will also support the development of new product verticals for AI-driven predictive software models for sudden cardiac death and cardio-embolic stroke, as well as a new therapeutic software solution to help physicians treat heart failure patients. Currently, inHEART is commercially available in the US and EU through a direct sales force model, with plans to establish a global distribution network in the coming months to further accelerate growth.
Funding supports commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum.
(English version by Catalina Apostoiu)